Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from ...

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many ...

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to ...

Through this collaboration, oncology practices using VieCure Halo Intelligence will be able to order and receive results for Guardant tests for therapy selection and recurrence monitoring ...

Guardant Health serves more than 60 countries globally with its tests, and this partnership with Hikma will improve access to Guardant's next-generation sequencing (NGS) tests in the Middle East ...

BofA raised Tempus AI's price forecast to $70 but maintained a Neutral rating due to valuation concerns. Guardant Health, Exact Sciences, and LabCorp received Buy ratings for AI-aligned precision ...

Guardant Health, Inc., a leading precision oncology company, today announced that it has entered into a common stock purchase agreement with Baillie Gifford on behalf of accounts that it manages ...